Aptevo Therapeutics Inc. Reports Second Quarter 2023 Net Loss of $7.95 Million
Company Records No Royalty Revenue; Focuses on Research and Development Efforts
Aptevo Therapeutics Inc.(APVTW), a biotechnology company special izing in the development of novel immunotherapies, has released its condensed consolidated financial statements for the second quarter of 2023. The company reported a net loss of $7.95 million for the three months ended June 30, 2023. Despite not generating any royalty revenue during this period, the company continued to allocate resources towards advancing its research and development initiatives.
Net Loss and Revenue Overview
Aptevo Therapeutics Inc. faced a net loss of $7.95 million for the second quarter of 2023. This loss comes as the company dedicated efforts and investments to propel its research and development endeavors. The absence of any royalty revenue during this period contributed to the net loss.
Financial Highlights
